Pb2048: efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective multicenter study

C. Chen,S. Ma,F. Yan,H. Zhao,X. Chu,H. Zhang,X. Deng,Z. Liu,D. Li,T. xiao,C. Yuan,Z. Wang,G. Liu,M. Hou,Y. Yu
DOI: https://doi.org/10.1097/01.hs9.0000851024.61601.a6
2022-01-01
HemaSphere
Abstract:Background: Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor currently used in the treatment of Myelofibrosis (MF). Ruxolitinib confirmed improvements in splenomegaly, MF-related symptoms and survival benefit in COMFORT and JUMP studies. At present, the real-world data on the efficacy and safety of ruxolitinib in the treatment of MF in China is still insufficient. Aims: The aim of this study was to evaluate the efficacy and safety of ruxolitinib in patients with MF and to provide guidance for the usage of ruxolitinib in MF in China. Methods: This was a retrospective, multicenter study of MF patients who received ruxolitinib treatment in Shandong province from August 2012 to December 2021. Data were analyzed using SPSS. Overall survival (OS) and Event-free survival (EFS) were estimated using the Kaplan– Meier method. Results: A total of 130 MF patients were recruited, among which 97 (74.6%) primary MF patients and 33 (25.4) secondary MF patients were involved. Most patients started at dose of 20 mg bid (n=44, 33.1%), while other patients started ruxolitinib treatment at lower doses, including 15 mg bid (n=29, 21.8%), 5 mg bid (n=26, 19.5%) and 10 mg bid (n=23, 17.3%). The most common adverse events (AEs) were anemia (23.1%), thrombocytopenia (15.4%), lung infection (9.2%) and elevated aminotransferase (5.4%). Overall, Ruxolitinib led to remarkable reductions in spleen length and MF-related symptoms in most patients. 74.7% (71/95) of patients experienced an improvement in splenomegaly at any time after medication with a median reduction of 33.3% (Fig. A). At week 24, 73.8% (45/61) of the evaluated patients had a ≥25% decrease in spleen length, therein 45.9% (28/61) reached a ≥50% decrease (Fig. B). 87.5% (70/80) of patients experienced decreased MPN-SAF TSS with a median of -63.4% (Fig. C). The median reduction of more than 50% from baseline in all MF symptoms was observed in 53 assessed patients (Fig. D). The estimated OS probability of Low/ Int-1 patients was 96.7% at 24 months. The estimated OS probability of Int-2/ High patients was 83.9% at 24 months (Fig. E). Primary causes of death on study included MF (n=7), lung infection (n=1), cerebrovascular accident (n=1) and AML (n=1). The median EFS of Low/ Int-1 patients was 21 months, while the median EFS of Int-2/ High patients was 8 months (Fig. F). Image:Summary/Conclusion: In summary, Chinese MF patients receiving ruxolitinib showed improved splenomegaly and MF-related symptoms. Besides no new safety concerns were found. Less adverse events were observed in lower risk of MF patients during ruxolitinib treatment. Generally, the efficacy and safety profiles of ruxolitinib in the treatment of Chinese MF patients were basicly consistent with other studies.
What problem does this paper attempt to address?